A complex, chronic, and debilitating condition, inflammatory bowel disease (IBD) affects roughly 3 million Americans, including those with Crohn's disease and ulcerative colitis.
The drug has received a nod from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).
The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or ...
Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Omvoh (mirikizumab) for approval in the ...
Crohn’s & Colitis UK are delighted to be awarded a grant of $638,000 from The Leona M. and Harry B. Helmsley Charitable Trust ...
Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...
The disease is more common than you may realize; a study led by the Crohn's & Colitis Foundation found nearly 1 in 100 people living in the U.S. have IBD. The two most common forms of IBD are Crohn's ...
Duvakitug is a monoclonal antibody commercialized by Sanofi, with a leading Phase II program in Ulcerative Colitis;Crohn's Disease (Regional Enteritis).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback